Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Evogene Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
EVGN
Nasdaq
8731
https://evogene.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Evogene Ltd
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- Apr 16th, 2024 11:00 am
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
- Apr 11th, 2024 11:00 am
Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry
- Apr 2nd, 2024 11:00 am
Evogene Announces Filing of Annual Report on Form 20-F
- Mar 28th, 2024 1:00 pm
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
- Mar 20th, 2024 1:00 pm
Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing
- Mar 19th, 2024 1:00 pm
Lavie Bio and Ceres Global Ag Corp. Collaborate to Include YalosTM Bio-Inoculant, in Regenerative Agriculture Initiatives in North America
- Mar 13th, 2024 1:00 pm
Evogene Ltd. (NASDAQ:EVGN) Q4 2023 Earnings Call Transcript
- Mar 8th, 2024 6:30 pm
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
- Mar 7th, 2024 2:20 pm
Evogene Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 7th, 2024 12:00 pm
AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides
- Mar 6th, 2024 12:00 pm
Casterra Announces New Agreements with Seed Producers in Brazil and Africa to Meet Growing Demand for its Elite Castor Seed Varieties
- Mar 5th, 2024 12:00 pm
Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva's Licensing Agreement Requirements
- Feb 28th, 2024 12:00 pm
Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024
- Feb 26th, 2024 12:00 pm
AgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive Officer
- Feb 22nd, 2024 12:00 pm
AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution
- Feb 21st, 2024 12:00 pm
Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide
- Feb 20th, 2024 12:00 pm
Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation
- Feb 6th, 2024 12:00 pm
Biomica CEO Set to Engage in Panel Discussion at 8th Annual European Microbiome Movement Summit
- Jan 23rd, 2024 12:00 pm
Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
- Jan 17th, 2024 12:00 pm
Scroll